787O Adjuvant immunotherapy with nivolumab (NIVO) versus observation in completely resected Merkel cell carcinoma (MCC): Disease-free survival (DFS) results from ADMEC-O, a randomized, open-label phase II trial
Becker, J.C., Ugurel, S., Leiter-Stoppke, U., Meier, F., Gutzmer, R., Haferkamp, S., Zimmer, L., Livingstone, E., Eigentler, T., Hauschild, A., Kiecker, F., Hassel, J.C., Mohr, P., Fluck, M., Thomas, I., Garzarolli, M., Grimmelmann, I., Drexler, K., Eckhardt, S., Schadendorf, D.
Published in Annals of oncology (01.09.2022)
Published in Annals of oncology (01.09.2022)
Get full text
Journal Article
1079P Comparison of effectiveness and safety of nivolumab monotherapy or in combination therapy with ipilimumab in therapy-naïve and pretreated patients with advanced melanoma within the German noninterventional study NICO
Gutzmer, R., Eigentler, T., Mohr, P., Weichenthal, M., Dücker, P., Gebhardt, C., Göppner, D., Grimmelmann, I., Haferkamp, S., Kähler, K.C., Meier, F., Pföhler, C., Sickmann, T., Sindrilaru, A., Terheyden, P., Ugurel, S., Ulrich, J., Utikal, J., Weishaupt, C., Schadendorf, D.
Published in Annals of oncology (01.09.2021)
Published in Annals of oncology (01.09.2021)
Get full text
Journal Article